Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation

Manish Sharma, Mei Jie Zhang, Xiaobo Zhong, Muneer H. Abidi, Görgün Akpek, Ulrike Bacher, Natalie S. Callander, Angela Dispenzieri, César O. Freytes, Henry C. Fung, Robert Peter Gale, Cristina Gasparetto, John Gibson, Leona A. Holmberg, Tamila L. Kindwall-Keller, Thomas R. Klumpp, Amrita Y. Krishnan, Heather J. Landau, Hillard M. Lazarus, Sagar LonialAngelo Maiolino, David I. Marks, Paulette Mehta, Joseph R Mikhael, Taiga Nishihori, Richard Olsson, Muthalagu Ramanathan, Vivek Roy, Bipin N. Savani, Harry C. Schouten, Emma Scott, Jason Tay, Luen Bik To, David H. Vesole, Dan T. Vogl, Parameswaran Hari

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Autologous hematopoietic cell transplantation (AHCT) for plasma cell myeloma is performed less often in people >70 years old than in people ≤70 years old. We analyzed 11,430 AHCT recipients for plasma cell myeloma prospectively reported to the Center for International Blood and Marrow Transplant Research between 2008 and 2011, representing the majority of US AHCT activity during this period. Survival (OS) was compared in 3 cohorts: ages 18 to 59 years (n= 5818), 60 to 69 years (n= 4666), and >70 years (n= 946). Median OS was not reached for any cohort. In multivariate analysis, increasing age was associated with mortality (P= .0006). Myeloma-specific mortality was similar among cohorts at 12%, indicating an age-related effect on nonmyeloma mortality. Analyses were performed in a representative subgroup comparing relapse rate, progression-free survival (PFS), and nonrelapse mortality (NRM). One-year NRM was 0% for age >70 years and 2% for other ages (P= not significant). The three-year relapse rate was 56% in age 18 to 59 years, 61% in age 60 to 69 years, and 63% age >70 (P= not significant). Three-year PFS was similar at 42% in age 18 to 59 years, 38% in age 60 to 69 years, and 33% in age >70 years (P= not significant). Postrelapse survival was significantly worse for the older cohort (P= .03). Older subjects selected for AHCT derived similar antimyeloma benefit without worse NRM, relapse rate, or PFS.

Original languageEnglish (US)
Pages (from-to)1796-1803
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Volume20
Issue number11
DOIs
StatePublished - Nov 1 2014

Fingerprint

Autologous Transplantation
Cell Transplantation
Mortality
Disease-Free Survival
Multiple Myeloma
Recurrence
Multivariate Analysis
Bone Marrow
Transplants
Survival
Research

Keywords

  • Autologous transplantation
  • Myeloma
  • Older patients

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Sharma, M., Zhang, M. J., Zhong, X., Abidi, M. H., Akpek, G., Bacher, U., ... Hari, P. (2014). Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation. Biology of Blood and Marrow Transplantation, 20(11), 1796-1803. https://doi.org/10.1016/j.bbmt.2014.07.013

Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation. / Sharma, Manish; Zhang, Mei Jie; Zhong, Xiaobo; Abidi, Muneer H.; Akpek, Görgün; Bacher, Ulrike; Callander, Natalie S.; Dispenzieri, Angela; Freytes, César O.; Fung, Henry C.; Gale, Robert Peter; Gasparetto, Cristina; Gibson, John; Holmberg, Leona A.; Kindwall-Keller, Tamila L.; Klumpp, Thomas R.; Krishnan, Amrita Y.; Landau, Heather J.; Lazarus, Hillard M.; Lonial, Sagar; Maiolino, Angelo; Marks, David I.; Mehta, Paulette; Mikhael, Joseph R; Nishihori, Taiga; Olsson, Richard; Ramanathan, Muthalagu; Roy, Vivek; Savani, Bipin N.; Schouten, Harry C.; Scott, Emma; Tay, Jason; To, Luen Bik; Vesole, David H.; Vogl, Dan T.; Hari, Parameswaran.

In: Biology of Blood and Marrow Transplantation, Vol. 20, No. 11, 01.11.2014, p. 1796-1803.

Research output: Contribution to journalArticle

Sharma, M, Zhang, MJ, Zhong, X, Abidi, MH, Akpek, G, Bacher, U, Callander, NS, Dispenzieri, A, Freytes, CO, Fung, HC, Gale, RP, Gasparetto, C, Gibson, J, Holmberg, LA, Kindwall-Keller, TL, Klumpp, TR, Krishnan, AY, Landau, HJ, Lazarus, HM, Lonial, S, Maiolino, A, Marks, DI, Mehta, P, Mikhael, JR, Nishihori, T, Olsson, R, Ramanathan, M, Roy, V, Savani, BN, Schouten, HC, Scott, E, Tay, J, To, LB, Vesole, DH, Vogl, DT & Hari, P 2014, 'Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation', Biology of Blood and Marrow Transplantation, vol. 20, no. 11, pp. 1796-1803. https://doi.org/10.1016/j.bbmt.2014.07.013
Sharma, Manish ; Zhang, Mei Jie ; Zhong, Xiaobo ; Abidi, Muneer H. ; Akpek, Görgün ; Bacher, Ulrike ; Callander, Natalie S. ; Dispenzieri, Angela ; Freytes, César O. ; Fung, Henry C. ; Gale, Robert Peter ; Gasparetto, Cristina ; Gibson, John ; Holmberg, Leona A. ; Kindwall-Keller, Tamila L. ; Klumpp, Thomas R. ; Krishnan, Amrita Y. ; Landau, Heather J. ; Lazarus, Hillard M. ; Lonial, Sagar ; Maiolino, Angelo ; Marks, David I. ; Mehta, Paulette ; Mikhael, Joseph R ; Nishihori, Taiga ; Olsson, Richard ; Ramanathan, Muthalagu ; Roy, Vivek ; Savani, Bipin N. ; Schouten, Harry C. ; Scott, Emma ; Tay, Jason ; To, Luen Bik ; Vesole, David H. ; Vogl, Dan T. ; Hari, Parameswaran. / Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation. In: Biology of Blood and Marrow Transplantation. 2014 ; Vol. 20, No. 11. pp. 1796-1803.
@article{c9f7df5ad6d54cefb4d5081481dbd4c1,
title = "Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation",
abstract = "Autologous hematopoietic cell transplantation (AHCT) for plasma cell myeloma is performed less often in people >70 years old than in people ≤70 years old. We analyzed 11,430 AHCT recipients for plasma cell myeloma prospectively reported to the Center for International Blood and Marrow Transplant Research between 2008 and 2011, representing the majority of US AHCT activity during this period. Survival (OS) was compared in 3 cohorts: ages 18 to 59 years (n= 5818), 60 to 69 years (n= 4666), and >70 years (n= 946). Median OS was not reached for any cohort. In multivariate analysis, increasing age was associated with mortality (P= .0006). Myeloma-specific mortality was similar among cohorts at 12{\%}, indicating an age-related effect on nonmyeloma mortality. Analyses were performed in a representative subgroup comparing relapse rate, progression-free survival (PFS), and nonrelapse mortality (NRM). One-year NRM was 0{\%} for age >70 years and 2{\%} for other ages (P= not significant). The three-year relapse rate was 56{\%} in age 18 to 59 years, 61{\%} in age 60 to 69 years, and 63{\%} age >70 (P= not significant). Three-year PFS was similar at 42{\%} in age 18 to 59 years, 38{\%} in age 60 to 69 years, and 33{\%} in age >70 years (P= not significant). Postrelapse survival was significantly worse for the older cohort (P= .03). Older subjects selected for AHCT derived similar antimyeloma benefit without worse NRM, relapse rate, or PFS.",
keywords = "Autologous transplantation, Myeloma, Older patients",
author = "Manish Sharma and Zhang, {Mei Jie} and Xiaobo Zhong and Abidi, {Muneer H.} and G{\"o}rg{\"u}n Akpek and Ulrike Bacher and Callander, {Natalie S.} and Angela Dispenzieri and Freytes, {C{\'e}sar O.} and Fung, {Henry C.} and Gale, {Robert Peter} and Cristina Gasparetto and John Gibson and Holmberg, {Leona A.} and Kindwall-Keller, {Tamila L.} and Klumpp, {Thomas R.} and Krishnan, {Amrita Y.} and Landau, {Heather J.} and Lazarus, {Hillard M.} and Sagar Lonial and Angelo Maiolino and Marks, {David I.} and Paulette Mehta and Mikhael, {Joseph R} and Taiga Nishihori and Richard Olsson and Muthalagu Ramanathan and Vivek Roy and Savani, {Bipin N.} and Schouten, {Harry C.} and Emma Scott and Jason Tay and To, {Luen Bik} and Vesole, {David H.} and Vogl, {Dan T.} and Parameswaran Hari",
year = "2014",
month = "11",
day = "1",
doi = "10.1016/j.bbmt.2014.07.013",
language = "English (US)",
volume = "20",
pages = "1796--1803",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation

AU - Sharma, Manish

AU - Zhang, Mei Jie

AU - Zhong, Xiaobo

AU - Abidi, Muneer H.

AU - Akpek, Görgün

AU - Bacher, Ulrike

AU - Callander, Natalie S.

AU - Dispenzieri, Angela

AU - Freytes, César O.

AU - Fung, Henry C.

AU - Gale, Robert Peter

AU - Gasparetto, Cristina

AU - Gibson, John

AU - Holmberg, Leona A.

AU - Kindwall-Keller, Tamila L.

AU - Klumpp, Thomas R.

AU - Krishnan, Amrita Y.

AU - Landau, Heather J.

AU - Lazarus, Hillard M.

AU - Lonial, Sagar

AU - Maiolino, Angelo

AU - Marks, David I.

AU - Mehta, Paulette

AU - Mikhael, Joseph R

AU - Nishihori, Taiga

AU - Olsson, Richard

AU - Ramanathan, Muthalagu

AU - Roy, Vivek

AU - Savani, Bipin N.

AU - Schouten, Harry C.

AU - Scott, Emma

AU - Tay, Jason

AU - To, Luen Bik

AU - Vesole, David H.

AU - Vogl, Dan T.

AU - Hari, Parameswaran

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Autologous hematopoietic cell transplantation (AHCT) for plasma cell myeloma is performed less often in people >70 years old than in people ≤70 years old. We analyzed 11,430 AHCT recipients for plasma cell myeloma prospectively reported to the Center for International Blood and Marrow Transplant Research between 2008 and 2011, representing the majority of US AHCT activity during this period. Survival (OS) was compared in 3 cohorts: ages 18 to 59 years (n= 5818), 60 to 69 years (n= 4666), and >70 years (n= 946). Median OS was not reached for any cohort. In multivariate analysis, increasing age was associated with mortality (P= .0006). Myeloma-specific mortality was similar among cohorts at 12%, indicating an age-related effect on nonmyeloma mortality. Analyses were performed in a representative subgroup comparing relapse rate, progression-free survival (PFS), and nonrelapse mortality (NRM). One-year NRM was 0% for age >70 years and 2% for other ages (P= not significant). The three-year relapse rate was 56% in age 18 to 59 years, 61% in age 60 to 69 years, and 63% age >70 (P= not significant). Three-year PFS was similar at 42% in age 18 to 59 years, 38% in age 60 to 69 years, and 33% in age >70 years (P= not significant). Postrelapse survival was significantly worse for the older cohort (P= .03). Older subjects selected for AHCT derived similar antimyeloma benefit without worse NRM, relapse rate, or PFS.

AB - Autologous hematopoietic cell transplantation (AHCT) for plasma cell myeloma is performed less often in people >70 years old than in people ≤70 years old. We analyzed 11,430 AHCT recipients for plasma cell myeloma prospectively reported to the Center for International Blood and Marrow Transplant Research between 2008 and 2011, representing the majority of US AHCT activity during this period. Survival (OS) was compared in 3 cohorts: ages 18 to 59 years (n= 5818), 60 to 69 years (n= 4666), and >70 years (n= 946). Median OS was not reached for any cohort. In multivariate analysis, increasing age was associated with mortality (P= .0006). Myeloma-specific mortality was similar among cohorts at 12%, indicating an age-related effect on nonmyeloma mortality. Analyses were performed in a representative subgroup comparing relapse rate, progression-free survival (PFS), and nonrelapse mortality (NRM). One-year NRM was 0% for age >70 years and 2% for other ages (P= not significant). The three-year relapse rate was 56% in age 18 to 59 years, 61% in age 60 to 69 years, and 63% age >70 (P= not significant). Three-year PFS was similar at 42% in age 18 to 59 years, 38% in age 60 to 69 years, and 33% in age >70 years (P= not significant). Postrelapse survival was significantly worse for the older cohort (P= .03). Older subjects selected for AHCT derived similar antimyeloma benefit without worse NRM, relapse rate, or PFS.

KW - Autologous transplantation

KW - Myeloma

KW - Older patients

UR - http://www.scopus.com/inward/record.url?scp=84908070200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908070200&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2014.07.013

DO - 10.1016/j.bbmt.2014.07.013

M3 - Article

C2 - 25046833

AN - SCOPUS:84908070200

VL - 20

SP - 1796

EP - 1803

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 11

ER -